リスク因子を背負った認知症治療研究

A Review of Clinical Studies Investigating Patients with Alzheimer's Disease having Genetic Risk Factors

アルツハイマー病を根本的に抑制する疾患修飾療法が現在開発中である。脳内に異常蓄積するアミロイドβをターゲットにした，免疫療法，セクレターゼ阻害薬，凝集阻害薬などがこれに含まれている。この過程で，ゲノム上のリスク遺伝子保有者における治療薬の有効性と副作用が異なる場合があることが報告されてきた。本論ではリスク遺伝子を有する患者群に関連した臨床試験に関して概説する。

Abstract

Aside from the current conventional pharmaceutical therapies that have limited effects on patients with Alzheimer's disease, disease-modifying therapies have been developed to inhibit the pathological processes of Alzheimer's disease. These include immunotherapies, β/γ secretase inhibitors, and aggregation inhibitors targeting amyloid β. The involvement of genetic risk factors in the effectiveness of such processes has been confirmed. For example, apolipoprotein E ε4 carriers have been reported to have a risk of ARIA (Amyloid Related Imaging Abnormality) as an adverse effect by those therapies. In this paper, we review clinical studies examining patients with Alzheimer's disease, having genetic risk factors.